SC 13G

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No.     )*

RxSight, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

78349D107

(CUSIP Number)

December 31, 2021

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 2 of 7

CUSIP No. 78349D107

(1)	Names of reporting persons RxSight I, LLC – 81-5132686
(2)	Check the appropriate box if a member of a group (see instructions) (a)  ☐        (b)  ☐
(3)	SEC use only
(4)	Citizenship or place of organization Delaware
Number of shares beneficially owned by each reporting person with:		(5)	Sole voting power 0
		(6)	Shared voting power 2,016,778(1)
		(7)	Sole dispositive power 0
		(8)	Shared dispositive power 2,016,778(1)
(9)	Aggregate amount beneficially owned by each reporting person 2,016,778(1)
(10)	Check if the aggregate amount in Row (9) excludes certain shares (see instructions)
(11)	Percent of class represented by amount in Row (9) 7.60%(1)(2)
(12)	Type of reporting person (see instructions) OO

Page 3 of 7

CUSIP No. 78349D107

(1)	Names of reporting persons William J. Link, Ph.D.
(2)	Check the appropriate box if a member of a group (see instructions) (a)  ☐        (b)  ☐
(3)	SEC use only
(4)	Citizenship or place of organization United States of America
Number of shares beneficially owned by each reporting person with:		(5)	Sole voting power 0
		(6)	Shared voting power 2,016,778(1)
		(7)	Sole dispositive power 0
		(8)	Shared dispositive power 2,016,778(1)
(9)	Aggregate amount beneficially owned by each reporting person 2,016,778(1)
(10)	Check if the aggregate amount in Row (9) excludes certain shares (see instructions)
(11)	Percent of class represented by amount in Row (9) 7.60%(1)(2)
(12)	Type of reporting person (see instructions) IN

Page 4 of 7

SCHEDULE 13G

Item 1(a) Name of issuer: RxSight, Inc.

Item 1(b) Address of issuer’s principal executive offices: 100 Columbia, Aliso Viejo, CA 92656

2(a) Name of person filing:

This Schedule 13G is being jointly filed by each of the following persons pursuant to Rule 13d-1 promulgated by the Securities and Exchange Commission pursuant to Section 13 of the Act:

(i) RxSight I, LLC, a Delaware limited liability company (“RxSight I”); and

(ii) William J. Link, Ph.D., who is a managing member of RxSight I.

RxSight I and Mr. Link are hereinafter collectively referred to as the “Reporting Persons.”

2(b) Address or principal business office or, if none, residence:

The business address of RxSight I is 11 Linda Isle, Newport Beach, CA 92660. The business address of Mr. Link is C/O RxSight, Inc., 100 Columbia, Aliso Viejo, CA 92656.

2(c) Citizenship:

See Item 2(a) above and Item 4 of each cover page.

2(d) Title of class of securities:

Common Stock, par value $0.001 per share

2(e) CUSIP No.:

78349D107

Item 3. If this statement is filed pursuant to §§240.13d–1(b) or 240.13d–2(b) or (c), check whether the person filing is a:

(a)	☐	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	☐	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	☐	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	☐	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a–8);
(e)	☐	An investment adviser in accordance with §240.13d–1(b)(1)(ii)(E);
(f)	☐	An employee benefit plan or endowment fund in accordance with §240.13d–1(b)(1)(ii)(F);
(g)	☐	A parent holding company or control person in accordance with §240.13d–1(b)(1)(ii)(G);
(h)	☐	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	☐	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a–3);
(j)	☐	A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);
(k)	☐	Group, in accordance with §240.13d–1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with§240.13d–1(b)(1)(ii)(J), please specify the type of institution:

Item 4. Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount beneficially owned: 2,016,778⁽¹⁾

(b) Percent of class: 7.60%⁽¹⁾⁽²⁾

Page 5 of 7

SCHEDULE 13G

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote: 0

(ii) Shared power to vote or to direct the vote: 2,016,778⁽¹⁾

(iii) Sole power to dispose or to direct the disposition of: 0

(iv) Shared power to dispose or to direct the disposition of: 2,016,778⁽¹⁾

(1) Reflects Common Stock of the Issuer (“Common Stock”) held by the Reporting Persons. The Reporting Persons obtained the Common Stock in connection with the initial public offering of the Common Stock (“IPO”), pursuant to which shares of the Issuer’s Series H Preferred Stock, par value $0.001 per share, held by the Reporting Persons were automatically converted on a one-for-one basis to shares of Common Stock prior to the closing of the IPO.

(2) By reason of the provisions of Rule 13d-3 of the Act, each of the Reporting Persons may be deemed to beneficially own the shares disclosed in this Schedule 13G.

Item 5. Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following  ☐.

Dissolution of a group requires a response to this item.

Not applicable.

Item 6. Ownership of More than 5 Percent on Behalf of Another Person.

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not applicable.

Item 8. Identification and Classification of Members of the Group.

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

Item 10. Certifications

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect other than activities solely in connection with a nomination under §240.14a-11.

Page 6 of 7

Signatures

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 14, 2022	Signature:	/s/ William J. Link, Ph.D.
	Name:	William J. Link, Ph.D.
	Title:	Individually and as a managing member of RxSight I, LLC

Page 7 of 7

EXHIBIT INDEX

Exhibit     No.	Description of Exhibit
99.1	Joint Filing Agreement dated as of February 14, 2022.

EX-99.1

Exhibit 99.1

AGREEMENT OF JOINT FILING

In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13G referred to below) on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock, par value $0.001 per share, of RxSight, Inc., a Delaware corporation, and that this agreement may be included as an exhibit to such joint filing.

Dated: February 14, 2022	RxSIGHT I, LLC, a Delaware limited liability company
	By:	/s/ William J. Link, Ph.D.
	Name:	William J. Link, Ph.D.
	Title:	Managing Member
	/s/ William J. Link, Ph.D.
	William J. Link, Ph.D.